chr1-97691776-G-A
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PM5PP3_StrongPP5_Strong
The ENST00000370192.8(DPYD):c.703C>T(p.Arg235Trp) variant causes a missense change. The variant allele was found at a frequency of 0.0000477 in 1,613,280 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as drug response (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R235Q) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000370192.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DPYD | NM_000110.4 | c.703C>T | p.Arg235Trp | missense_variant | 7/23 | ENST00000370192.8 | NP_000101.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DPYD | ENST00000370192.8 | c.703C>T | p.Arg235Trp | missense_variant | 7/23 | 1 | NM_000110.4 | ENSP00000359211.3 | ||
DPYD | ENST00000474241.1 | n.467C>T | non_coding_transcript_exon_variant | 4/4 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000395 AC: 6AN: 151876Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000796 AC: 20AN: 251292Hom.: 0 AF XY: 0.000118 AC XY: 16AN XY: 135818
GnomAD4 exome AF: 0.0000486 AC: 71AN: 1461404Hom.: 0 Cov.: 30 AF XY: 0.0000619 AC XY: 45AN XY: 726998
GnomAD4 genome AF: 0.0000395 AC: 6AN: 151876Hom.: 0 Cov.: 32 AF XY: 0.0000270 AC XY: 2AN XY: 74164
ClinVar
Submissions by phenotype
Dihydropyrimidine dehydrogenase deficiency Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | The DPYD c.703C>T (p.Arg235Trp) missense variant has been reported in one study in a compound heterozygous state with a frameshift variant in one individual with dihydropyrimidine dehydrogenase (DPD) deficieny (Vreken et al. 1997). The patient's mother was heterozygous for the p.Arg235Trp variant and had intermediate DPD activity, while the patient's father was homozygous for the frameshift variant and was completely DPD deficient (Vreken et al. 1997). Control data are unavailable for this variant, which is reported at a frequency of 0.0002 in the South Asian population of the Exome Aggregation Consortium. Expression of the p.Arg235Trp variant in E. coli showed DPD enzyme activity of approximately 1% that of the wild type enzyme. Crystal structure analysis of DPD indicated that the p.Arg235Trp variant interferes directly with cofactor and/or substrate binding (Dobritzsch et al., 2001). Offer et al. (2014) expressed the variant in an isogenic mammalian system and found a dramatic reduction in activity (12.5%–25%) compared to wild type. The evidence for this variant is limited. The p.Arg235Trp variant is classified as unknown significance, but suspicious for pathogenicity for dihydropyrimidine dehydrogenase deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 13, 2024 | - - |
fluorouracil response - Other Other:1
drug response, reviewed by expert panel | curation | PharmGKB | Mar 24, 2021 | PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance. Drug-variant association: Other |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at